moxonidine
Moxonidine (INN) is a new-generation alpha-2/imidazoline receptor agonist antihypertensive drug licensed for the treatment of mild to moderate essential hypertension. It may have a role when thiazides, beta-blockers, ACE inhibitors, and calcium channel blockers are not appropriate or have failed to control blood pressure. In addition, it demonstrates favourable effects on parameters of the insulin resistance syndrome, apparently independent of blood pressure reduction. It is also a growth hormone releaser. It is manufactured by Solvay Pharmaceuticals under the brand name Physiotens and Moxon. — Wikipedia
Clinical trial activity
8 trials · 5 clinical orgs · 0 marketing orgs
Earliest trial started Jan 11, 2010 (NCT05147753)
Timeline
2010s
- Jan 1, 2019
Earliest Phase 1 Sponsor(trial)
Indications
Approved for
Mechanism of action
- NischarinAGONIST
NISCH agonist
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaMoxonidine ↗
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05312892 | Phase 1/Phase 2 (Phase 2) | May 20, 2022 | Vanderbilt University |
| NCT04329806 | Phase 1 | May 31, 2020 | National Heart, Lung, and Blood Institute (NHLBI), Vanderbilt University |
| NCT04140721 | Early Phase 1 (Phase 1) | Dec 1, 2019 | National Heart, Lung, and Blood Institute (NHLBI), Vanderbilt University |
| NCT04050410 | Early Phase 1 (Phase 1) | Aug 1, 2019 | National Heart, Lung, and Blood Institute (NHLBI), Vanderbilt University |
| NCT04023565 | Phase 4 | Mar 11, 2019 | Volgograd State Medical University |
| NCT04479813 | Phase 4 | Jul 8, 2015 | University of Western Australia |
| NCT04474899 | Phase 4 | Jun 24, 2015 | University of Western Australia |
| NCT05147753 | Phase 4 | Jan 11, 2010 | Aristotle University of Thessaloniki |
Organizations
Research & Development (5)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Vanderbilt University | Academic/Hospital | 4 | 4 | 2 | 2019 |
| National Heart, Lung, and Blood Institute (NHLBI) | Government | 3 | 0 | 1 | 2019 |
| University of Western Australia | Academic/Hospital | 2 | 2 | 1 | 2015 |
| Aristotle University of Thessaloniki | Academic/Hospital | 1 | 1 | 1 | 2010 |
| Volgograd State Medical University | Academic/Hospital | 1 | 1 | 1 | 2019 |